BioNTech SE (22UA) — Financial Flexibility Index

Latest as of March 2026: -0.14x

BioNTech SE (22UA) has a Financial Flexibility Index of -0.14x as of March 2026. Free cash flow of €-342.10 Million (operating CF €-421.00 Million minus capex €78.90 Million) represents 0% of total liabilities (€2.38 Billion). Also explore BioNTech SE equity growth rate to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.14x
Free Cash Flow / Total Liabilities

Free Cash Flow

€-342.10 Million
Operating CF − Capex

Total Liabilities

€2.38 Billion
EUR

Capital Expenditures

€78.90 Million
EUR

BioNTech SE Financial Flexibility Index (2017–2025)

Historical Financial Flexibility Index trend for BioNTech SE across 9 annual periods. Check BioNTech SE strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Annual Financial Flexibility Index for BioNTech SE (2017–2025)

Year-by-year free cash flow to debt coverage for BioNTech SE. For the full company profile including market capitalisation, see BioNTech SE stock valuation.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 0.44x €1.21 Billion €456.00 Million €2.76 Billion ▲ +106.0%
2024 0.21x €660.00 Million €207.70 Million €3.12 Billion ▼ -90.4%
2023 2.20x €6.08 Billion €5.37 Billion €2.76 Billion ▼ -49.1%
2022 4.32x €13.94 Billion €13.58 Billion €3.22 Billion ▲ +1573.9%
2021 0.26x €1.02 Billion €889.70 Million €3.94 Billion ▲ +365.9%
2020 0.06x €52.50 Million €-13.50 Million €946.77 Million ▲ +110.5%
2019 -0.53x €-159.90 Million €-198.50 Million €304.15 Million ▼ -600.3%
2018 -0.08x €-28.98 Million €-58.88 Million €385.99 Million ▼ -12.4%
2017 -0.07x €-28.24 Million €-52.56 Million €422.92 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities